ATP-Based Tumorchemosensitivity Assay In Gastric Cancer In Vitro Drug Sensitivity Test

Due to individual differences in anti-cancer drugs, multiple drug resistance and other factors, cancer patients on the drug sensitivity and resistance are different, and the cancer of the stomach the heterogeneity of the tumor cells of gastric cancer, even the same histological type of tumor may have different sensitivity to the same chemotherapy drugs; Therefore, stomach cancer (especially advanced gastric carcinoma) is still without chemotherapy regimens at present,the effect of gastric cancer chemotherapy not ideal, at present the effective rate of chemotherapy is around50%, about half of patients are not sensitive to initial chemotherapy (primary resistance). Due to most of chemotherapy has cytotoxicity combination of drug resistance and serious side-effects will take place if improper treatment, and ultimately lead to treatment failure. Therefore, first chemotherapy drug use is sensitive critical.Before chemotherapy to detect the sensitivity of the patient tumor cells to chemotherapeutic drugs,improve the pertinence and accuracy of the chemotherapy drug, accurate prediction of in vivo therapeutic effect, in order to filter out relatively effective chemotherapy drugs for patients, reduce the occurrence of blindness and drug resistance. It provides a scientific basis for clinicians to determine combination plots and carry out individualized treatment, in order to improve the clinical effect, extended survival of patients.Objective:ATP-tumor in vitro chemosensitivity assay (ATP-TCA) in gastric cancer cells in vitro sensitivity to different chemotherapeutic drugs, gastric cancer patients with individualized chemotherapy.Methods:ATP-tumor in vitro chemosensitivity assay (ATP-TCA) was used to determine the effect of10chemotherapy drugs sensitivity of41gastric carcinoma specimens freshly-taken from palliative resection or ascites,(FolFox、Fo1F1R1、ECF、DCF、DC、IC、PTX+5-FU、PTX+EPI、 GEM+DDP、CF); ATP-TCA predict clinical chemotherapy was received by38patients with advanced gastric cancer. At the same time, select41advanced stomach cancer patients of similar general information in the same period who accepted conventional chemotherapy as controls, to observe the clinical efficacy of4courses of treatment. Results:The evaluability rate of ATP-TCA was92.6%.The sensitive rate of EPI+DDP+5Fu、 PTX+5-FU、DOC+5Fu+DDP、GEM+DDP、PTX+EPI、5Fu+L-OHP+CF、DOC+DDP、 DDP+5-Fu、CPT-11+DDP、5Fu+L-OHP+CPT-11was:65.8%、52.6%、44.7%、39.5%、36.8%、26.3%、23.7%、13.2%、7.9%、5.3%.Clinical results:experimental group compared with control group:ORR was73.7%and56.1%(P<0.05, x2=4.226),SD was18.4%and24.4%(P>0.05, x2=0.416).Conclusions:1The sensitivity of gastric cancer to chemotherapeutic drug is relatively low, while there is significant individual heterogeneous.2ATP-TCA system can be successfully used to evaluate gastric cancer. The programs of EPI+5-Fu+DDP、PTX+5-FU、DOC+5Fu+DDP have relatively high in vitro anti-gastric cancer activity.3ATP-TCA in vitro screening of gastric cancer chemotherapy drugs, to avoid the tumor’s primary drug resistance and blind medication.4ATP-TCA has high sensitivity, good stability, easy, fast, and it is high-efficiency to guide clinical chemotherapy, it can be used for personalized chemotherapy of gastric cancer.